Susceptibility genes for acute exacerbation of COPD and their application in predicting susceptibility to acute exacerbation of COPD

By detecting the mutation or expression of susceptible genes in patients with COPD, and using high-throughput sequencing technology to identify specific gene differences, the problem of insufficient susceptibility to acute exacerbation of COPD in the existing technology is solved, and the acuteness of COPD is achieved Efficient prediction and diagnosis of aggravation.

CN114410772BActive Publication Date: 2024-12-03PEKING UNION MEDICAL COLLEGE HOSPITAL +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202210099711.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-01-28
Filing Date
2022-01-27
Publication Date
2024-12-03
Estimated Expiration
2042-01-27

AI Technical Summary

Technical Problem

The prior art has achieved very limited results in predicting the acute exacerbation of COPD, and it is difficult to effectively predict whether the subject to be tested is susceptible to acute exacerbation of COPD.

Method used

By detecting whether the subject to be tested contains or contains susceptible genes, or whether its genes are mutations or expression levels, using high-throughput sequencing or generation sequencing technology, ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3 are identified. Specific mutations or expression differences in genes such as ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and MRC2 are used to aid in predicting or diagnosing susceptibility to acute exacerbations of COPD.

Benefits of technology

Through genomics technology, blood samples from patients with acute exacerbation of COPD were collected, and the differences in total exon genes in patients with stable and acute exacerbation of COPD were compared. 20 AECOPD-specific susceptibility genes were found, which achieved chronic obstruction. Highly specific prediction of acute pulmonary aggravation has wide application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention discloses a COPD acute exacerbation susceptibility gene and its application in predicting susceptibility to COPD acute exacerbation. The present invention collects clinical specimens such as blood from COPD acute exacerbation patients, performs blood DNA whole exon detection on COPD patients through genomics technology, and obtains 20 AECOPD-specific susceptibility genes by comparing the whole exon gene differences between COPD patients in the stable phase and acute exacerbation phase; through the gene detection of the validation cohort, it is found that among these 20 genes, highly specific genes for predicting COPD acute exacerbation are identified, which can be used to screen COPD acute exacerbation susceptible patients, and provide a basis for future larger clinical sample studies to verify markers for prognosis and recurrence of susceptible COPD acute exacerbation, and has broad application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the biomedical field, specifically to genes susceptible to acute exacerbations of COPD and their application in predicting susceptibility to acute exacerbations of COPD. Background Technology

[0002] Chronic obstructive pulmonary disease (COPD) is a group of chronic airway diseases characterized by persistent respiratory symptoms and airflow limitation. According to the World Health Organization, COPD is projected to become the fifth leading cause of global economic burden and the third leading cause of death worldwide by 2020. Multiple factors, including smoking, air pollution, and occupational exposure, can lead to COPD. Only 10%–20% of smokers develop COPD, while 25% of COPD patients never smoke, indicating that COPD is the result of both genetic and environmental factors. Clinically, COPD is divided into stable phases and acute exacerbations based on symptom variability.

[0003] Acute exacerbations of COPD (AECOPD) are significant events in the clinical course of COPD and a major determinant of the health status and prognosis of COPD patients. Frequent AECOPD leads to deterioration of lung function and increased mortality. Clinically, AECOPD is an acute-onset process in which COPD patients experience an acute exacerbation of respiratory symptoms (typically manifested as increased dyspnea, severe cough, increased sputum volume, and / or purulent sputum), exceeding daily variability and requiring a change in medication. AECOPD is a clinically excluded diagnosis where clinical and / or laboratory examinations do not reveal other explainable specific diseases (e.g., pneumonia, congestive heart failure, pneumothorax, pleural effusion, pulmonary embolism, and arrhythmias). With treatment, the worsening of respiratory symptoms may improve, and typical symptoms will resolve within days to weeks.

[0004] There are many studies on acute exacerbations of COPD both domestically and internationally, but the results achieved in predicting genes associated with acute exacerbations are very limited. Summary of the Invention

[0005] The technical problem to be solved by this invention is how to predict whether a subject is susceptible to acute exacerbations of COPD.

[0006] To solve the above-mentioned technical problems, the present invention provides any of the following applications:

[0007] 1. The application of substances that detect whether susceptibility genes of test subjects have mutated in the preparation of products for predicting or assisting in predicting whether test subjects are susceptible to acute exacerbations of COPD; wherein the susceptibility genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and / or MRC2 genes;

[0008] 2. The application of substances that detect whether a test subject contains susceptibility genes in the preparation of products for predicting or assisting in predicting whether a test subject is susceptible to acute exacerbations of COPD; the susceptibility genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and / or MRC2 genes;

[0009] 3. The application of substances that detect the expression levels of susceptibility genes in the preparation of products for predicting or assisting in predicting whether a subject is susceptible to acute exacerbations of COPD; the susceptibility genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and / or MRC2 genes;

[0010] 4. The application of substances that detect whether the susceptibility genes of the test subject have been mutated in the preparation of products for screening or assisting in the screening of patients susceptible to acute exacerbations of COPD; the susceptibility genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and / or MRC2 genes;

[0011] 5. The application of substances for detecting whether the subject contains susceptibility genes in the preparation of products for screening or assisting in screening patients susceptible to acute exacerbations of COPD; the susceptibility genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and / or MRC2 genes;

[0012] 6. Application of substances for detecting the expression levels of susceptibility genes in the preparation of products for screening or assisting in the screening of patients susceptible to acute exacerbations of COPD; wherein the susceptibility genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and / or MRC2 genes;

[0013] 7. Application of substances for detecting whether susceptibility genes of the test subject have mutated in the preparation of diagnostic or auxiliary diagnostic products for acute exacerbations of COPD; wherein the susceptibility genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and / or MRC2 genes;

[0014] 8. The application of substances that detect whether the subject contains susceptibility genes in the preparation of diagnostic or auxiliary diagnostic products for acute exacerbations of COPD; wherein the susceptibility genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and / or MRC2 genes;

[0015] 9. The application of substances for detecting the expression levels of susceptibility genes in the preparation of diagnostic or auxiliary diagnostic products for acute exacerbations of COPD; wherein the susceptibility genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and / or MRC2 genes.

[0016] Substances for detecting whether a test subject contains a susceptibility gene, or substances for detecting whether a susceptibility gene in a test subject has mutated, or substances for detecting the expression level of a susceptibility gene in a test subject, are also within the scope of protection of this invention.

[0017] In the above text, the substance used to detect whether the test subject contains a susceptibility gene may be, but is not limited to, reagents or kits used to detect whether the test subject contains a susceptibility gene using high-throughput sequencing or first-generation sequencing methods, or systems containing reagents, kits, sequencing instruments, and / or software or modules used for sequence analysis. The reagents may be, but are not limited to, various primers and probes used in high-throughput sequencing or primers and probes required in first-generation sequencing. The substance used to detect whether the test subject contains a susceptibility gene may be a substance that specifically detects the susceptibility gene or a substance that non-specifically detects the susceptibility gene.

[0018] The substance used to detect whether the susceptibility gene of the test subject has mutated may be, but is not limited to, reagents or kits used to detect whether the test subject contains the susceptibility gene using high-throughput sequencing or first-generation sequencing methods, or systems containing reagents, kits, sequencing instruments, and / or software or modules used for sequence analysis. The reagents may be, but are not limited to, various primers and probes used in high-throughput sequencing or primers and probes required in first-generation sequencing. The substance used to detect whether the susceptibility gene of the test subject has mutated may be a substance that specifically detects whether the susceptibility gene has mutated or a substance that non-specifically detects whether the susceptibility gene has mutated.

[0019] The substance used to detect the expression level of susceptibility genes in the test subject may be, but is not limited to, primers for quantitative gene expression analysis, other reagents, instruments for quantitative gene expression analysis, and / or software and / or post-analysis modules for data analysis. The substance used to detect the expression level of susceptibility genes in the test subject may be a substance that specifically detects the expression level of the susceptibility gene or a substance that non-specifically detects the expression level of the susceptibility gene.

[0020] Whether the susceptibility gene has mutated can be at least one of the following:

[0021] A mutation in the ITK gene at chromosome 5, position 156608135, REF / ALT:G / T; NM_005546:exon1:c.138+9G>T, 5q33.3;

[0022] A mutation in the ITK gene at position 156635995 on chromosome 5, REF / ALT: C / G; 5q33.3;

[0023] The ITK gene mutation at 156675967 on chromosome 5, rs34482255, REF / ALT:C / T; 5q33.3;

[0024] The ROCK1 gene mutation at 18562720 on chromosome 18, REF / ALT:T / C; NM_005406:exon21:c.2559+4A>G, 18q11.1;

[0025] The ROCK1 gene mutation is located at 18619507 on chromosome 18, rs370467228, REF / ALT: C / T; 18q11.1;

[0026] The ADCY9 gene has a mutation at position 4165128 on chromosome 16, with REF / ALT: C / A; 16p13.3;

[0027] The ITGA2B gene mutation is located at 42449770 on chromosome 17, rs761164933, REF / ALT: G / A; 17q21.31;

[0028] The ITGA2B gene mutation is located at 42457115 on chromosome 17, rs539187844, REF / ALT: G / A; 17q21.31;

[0029] The ITGA2B gene mutation at position 42460918 on chromosome 17, REF / ALT: C / T; 17q21.31;

[0030] The ITGA2B gene mutation is located at 42462982 on chromosome 17, rs749432805, REF / ALT:G / C; 17q21.31;

[0031] The mutation at 149497184 on chromosome 5 of the PDGFRB gene is rs754945283, REF / ALT:G / A; 5q32;

[0032] The mutation at 149503834 on chromosome 5 of the PDGFRB gene is rs768318526, REF / ALT: A / T; 5q32;

[0033] The mutation at 149512332 on chromosome 5 of the PDGFRB gene is rs200684708, REF / ALT:G / A; 5q32;

[0034] The FGFR3 gene mutation is located at 1795748 on chromosome 4, rs553265665, REF / ALT:G / C; 4p16.3;

[0035] The FGFR3 gene mutation is located at 1803138 on chromosome 4, rs577990843, REF / ALT:C / G; 4p16.3;

[0036] The FGFR3 gene mutation is located at 1806569 on chromosome 4, rs182935140, REF / ALT:G / A; 4p16.3;

[0037] A mutation in the FGFR3 gene at position 1807899 on chromosome 4, REF / ALT: A / C; 4p16.3;

[0038] The FGFR3 gene mutation is located at 1808659 on chromosome 4, rs56266857, REF / ALT: G / A; 4p16.3;

[0039] A mutation in the FGFR3 gene at position 1808952 on chromosome 4, REF / ALT: C / T; 4p16.3;

[0040] The mutation of the SERPINA3 gene at chromosome 14, position 95081148, rs116880457, REF / ALT: C / T; 14q32.13;

[0041] A mutation in the SERPINA3 gene at position 95085620 on chromosome 14, REF / ALT: G / A; 14q32.13;

[0042] The mutation of the SERPINA3 gene at position 95085652 on chromosome 14, rs536399107, REF / ALT: G / A; 14q32.13;

[0043] The mutation of the SERPINA3 gene at position 95088683 on chromosome 14, rs142398813, REF / ALT:T / C; 14q32.13;

[0044] The ITPR1 gene mutation is located at 4715070 on chromosome 3, rs200199463, REF / ALT: G / A; 3p26.1;

[0045] The ITPR1 gene has a mutation at position 4808292 on chromosome 3, REF / ALT: G / A; 3p26.1;

[0046] The ITPR1 gene mutation is located at 4856139 on chromosome 3, rs367632214, REF / ALT: A / G; 3p26.1;

[0047] The mutation at 117171053 on chromosome 7 of the CFTR gene is rs141723617, REF / ALT:T / C; 7q31.2;

[0048] The mutation in the CFTR gene at position 117171122 on chromosome 7, rs35516286, REF / ALT:T / C; 7q31.2;

[0049] The mutation at 117175372 on chromosome 7 of the CFTR gene is rs121909046, REF / ALT: A / G; 7q31.2;

[0050] The mutation in the CFTR gene at position 117176719 on chromosome 7 is rs112162204, REF / ALT:C / G; 7q31.2;

[0051] The mutation in the CFTR gene at position 117267592 on chromosome 7, rs1800120, REF / ALT:G / A; 7q31.2;

[0052] The mutation in the CFTR gene at position 117267766 on chromosome 7 is rs1800123, REF / ALT:C / T; 7q31.2;

[0053] The mutation in the CFTR gene at chromosome 7, 117304869, rs397508670, REF / ALT:C / T, 7q31.2;

[0054] The mutation in the USP24 gene at position 55559639 on chromosome 1, REF / ALT:C / A, 1p32.3;

[0055] The mutation in the USP24 gene on chromosome 1, at position 55569610, REF / ALT: A / G, 1p32.3;

[0056] The mutation at 55603184 on chromosome 1 of the USP24 gene is rs185201791, REF / ALT:G / A, NM_015306:exon28:c.3201+4C>T, 1p32.3;

[0057] The mutation at 55604394 on chromosome 1 of the USP24 gene is REF / ALT:T / C, NM_015306:exon26:c.2818-3A>G, 1p32.3;

[0058] The mutation in the USP24 gene at position 55613326 on chromosome 1, rs190706465, REF / ALT:C / T, 1p32.3;

[0059] The mutation at 55631552 on chromosome 1 of the USP24 gene is rs142154143, REF / ALT:A / T, NM_015306:exon7:c.927+6T>A, 1p32.3;

[0060] The mutation in the USP24 gene at position 55631613 on chromosome 1, REF / ALT: A / T, 1p32.3;

[0061] The mutation of the SAA1 gene at position 18291340 on chromosome 11, rs776323374, REF / ALT:T / C, 11p15.1;

[0062] The TEK gene mutation is located at 27204927 on chromosome 9, rs202131936, REF / ALT:G / C, 9p21.2;

[0063] The TEK gene mutation at 27220040 on chromosome 9, rs201242194, REF / ALT:C / G, NM_000459:exon21:c.3104-7C>G; NM_001290077:exon20:c.2975-7C>G; NM_001290078:exon19:c.2660-7C>G, 9p21.2;

[0064] The TEK gene mutation at 27228307 on chromosome 9, REF / ALT: A / C, NM_000459: exon22: c.3300+4A>C; NM_001290077: exon21: c.3171+4A>C; NM_001290078: exon20: c.2856+4A>C, 9p21.2;

[0065] The SPTBN2 gene mutation is located at 66455721 on chromosome 11, rs571837788, REF / ALT:G / A, 11q13.2;

[0066] The SPTBN2 gene mutation at chromosome 11, position 66457417, rs750335105, REF / ALT:G / T, NM_006946:exon28:c.5811-3C>A, 11q13.2;

[0067] The SPTBN2 gene mutation is located at 66460505 on chromosome 11, rs143640999, REF / ALT:C / T, 11q13.2;

[0068] The SPTBN2 gene mutation is located at 66461669 on chromosome 11, rs373270554, REF / ALT:G / A, 11q13.2;

[0069] The SPTBN2 gene mutation is located at 66472288 on chromosome 11, rs548188891, REF / ALT:G / A, 11q13.2;

[0070] The SPTBN2 gene mutation is located at 66472461 on chromosome 11, REF / ALT:C / A, 11q13.2;

[0071] The PLXNA4 gene mutation is located at 131817833 on chromosome 7, rs200763664, REF / ALT:G / A, 7q32.3;

[0072] The PLXNA4 gene mutation is located at 131870101 on chromosome 7, REF / ALT:C / T, 7q32.3;

[0073] The PLXNA4 gene mutation is located at 131908288 on chromosome 7, rs138963899, REF / ALT:C / T, 7q32.3;

[0074] The mutation of the PLXNA4 gene at 131908302 on chromosome 7, rs200493064, REF / ALT:C / T, 7q32.3;

[0075] The PLXNA4 gene mutation is located at 132174160 on chromosome 7, rs754782288, REF / ALT:C / T, 7q32.3;

[0076] The PLXNA4 gene mutation is located at 132192417 on chromosome 7, rs779570289, REF / ALT:T / G, 7q32.3;

[0077] The SPTA1 gene mutation is located at 158582725 on chromosome 1, REF / ALT:T / G, 1q23.1;

[0078] The SPTA1 gene mutation at chromosome 158590207, rs761106571, REF / ALT:T / C, 1q23.1;

[0079] The SPTA1 gene mutation at chromosome 158592822, rs768854133, REF / ALT:G / A, 1q23.1;

[0080] The SPTA1 gene mutation is located at 158597458 on chromosome 1, rs201233455, REF / ALT:C / T, 1q23.1;

[0081] The SPTA1 gene mutation is located at 158606509 on chromosome 1, rs749176177, REF / ALT:A / T, 1q23.1;

[0082] The SPTA1 gene mutation is located at 158613136 on chromosome 1, rs187916559, REF / ALT:G / A, 1q23.1;

[0083] The SPTA1 gene mutation is located at 158613172 on chromosome 1, REF / ALT: A / G, 1q23.1;

[0084] The SPTA1 gene mutation is located at 158637705 on chromosome 1, rs747716571, REF / ALT:G / A, 1q23.1;

[0085] The SPTA1 gene mutation is located at 158653225 on chromosome 1, rs3737521, REF / ALT:G / A, 1q23.1;

[0086] The PLG gene mutation at 161152897 on chromosome 6, rs747448179, REF / ALT:C / G, 6q26;

[0087] The mutation at chromosome 1, 206903451, of the MAPKAPK2 gene is REF / ALT:C / T, NM_004759:exon5:c.691+8C>T; NM_032960:exon5:c.691+8C>T, 1q32.1;

[0088] The mutation of the MAPKAPK2 gene at chromosome 1, position 206904606, REF / ALT: A / G, 1q32.1;

[0089] The mutation of the LAMA3 gene at position 21422714 on chromosome 18, REF / ALT:G / T, 18q11.2;

[0090] The mutation of the LAMA3 gene at chromosome 18, position 21447864, rs552326056, REF / ALT:C / T, 18q11.2;

[0091] The mutation at chromosome 18, position 21474864, of the LAMA3 gene is rs766873824, REF / ALT:C / T, NM_000227:exon7:c.635-7C>T; NM_001127717:exon44:c.5462-7C>T; NM_001127718:exon7:c.635-7C>T; NM_198129:exon44:c.5462-7C>T, 18q11.2;

[0092] The mutation in the LAMA3 gene at position 21494393 on chromosome 18 is rs184581808, REF / ALT:G / T, 18q11.2;

[0093] The mutation of the LAMA3 gene at chromosome 18, 21495335, rs781529313, REF / ALT: A / G, 18q11.2;

[0094] The mutation of the LAMA3 gene at 21508101 on chromosome 18, rs776754771, REF / ALT:C / T, 18q11.2;

[0095] The mutation of the LAMA3 gene at chromosome 18, 21523934, rs117056996, REF / ALT:C / T, 18q11.2;

[0096] The mutation of the LAMA3 gene at position 21530049 on chromosome 18, REF / ALT: A / C, 18q11.2;

[0097] The mutation of the P4HB gene at chromosome 17, position 79804369, rs200205336, REF / ALT:G / A, 17q25.3;

[0098] The P4HB gene mutation is located at 79804909 on chromosome 17, rs756125688, REF / ALT:T / C, 17q25.3;

[0099] The mutation of the MRC2 gene at chromosome 17, position 60751531, rs575846013, REF / ALT:G / A, 17q23.2;

[0100] The mutation of the MRC2 gene at chromosome 17, position 60768366, REF / ALT:C / T, 17q23.2.

[0101] In the above text, REF / ALT represents the reference genome nucleotide / mutant genome nucleotide.

[0102] This invention collects clinical specimens such as blood from patients with acute exacerbations of COPD and uses genomics technology to perform whole-exome DNA analysis on COPD patients. By comparing the differences in whole-exome genes between COPD patients in the stable phase and those in the acute exacerbation phase, 20 AECOPD-specific susceptibility genes were obtained. Subsequent validation cohort duplication gene analysis revealed highly specific genes for predicting acute exacerbations of COPD among these 20 genes. These genes can be used to screen patients susceptible to acute exacerbations of COPD and have broad application prospects in the future. Attached Figure Description

[0103] Figure 1 This represents the sequencing depth of the initial sample.

[0104] Figure 2 The results show the coverage depth (left coordinate) and coverage rate (right coordinate) of the initial queue samples.

[0105] Figure 3 The results of Phenolyzer analysis are for the initial queue samples.

[0106] Figure 4 To verify the Phenolyzer analysis results of the queue samples.

[0107] Figure 5 The results of ROC curve analysis for each gene are shown. Detailed Implementation

[0108] The present invention will now be described in further detail with reference to specific embodiments. The given embodiments are merely illustrative of the invention and not intended to limit its scope. The embodiments provided below can serve as a guide for further improvements by those skilled in the art and do not constitute a limitation on the invention in any way.

[0109] Unless otherwise specified, the experimental methods used in the following examples are conventional methods, performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the materials, reagents, instruments, etc., used in the following examples are commercially available.

[0110] Example 1

[0111] I. Sample Information

[0112] The initial cohort sample information is shown in Table 1, and the validation cohort sample information is shown in Table 2. Peripheral blood samples were used. N represents patients with stable COPD, and P represents patients with acute exacerbations of COPD. Inclusion criteria were: all patients met the diagnostic criteria for COPD; all patients had a forced expiratory volume in one second (FEV1) / forced vital capacity (FVC) ratio <70%; and stable patients had no acute exacerbations within the three months prior to sampling. An acute exacerbation was defined as an exacerbation requiring a change in the original treatment plan. Exclusion criteria were: patients with bronchial asthma, lung tumors, tuberculosis, interstitial lung disease, or other chronic lung diseases.

[0113] Table 1. Initial Queue Sample Information

[0114]

[0115]

[0116] Table 2. Validation Queue Sample Information

[0117]

[0118]

[0119] Among them, there were 32 patients with stable COPD (S1-S32) and 50 patients with acute exacerbations of COPD (A1-A51, excluding A49). Table 1 shows 22 patients with stable COPD and 33 patients with acute exacerbations of COPD; Table 2 shows 10 patients with stable COPD and 17 patients with acute exacerbations of COPD.

[0120] II. Experimental Procedure

[0121] 1. DNA sample detection

[0122] There are two methods for detecting DNA samples:

[0123] (1) Agarose gel electrophoresis was used to analyze the degree of DNA degradation and whether there was RNA or protein contamination.

[0124] (2) Qubit 3.0 accurately quantifies DNA concentration. DNA samples with a concentration of 0.6 μg or higher were used for library construction.

[0125] 2. Database creation and capture

[0126] Novogene used Agilent's liquid-phase chip capture system to efficiently enrich human whole-exon DNA, followed by high-throughput, high-depth sequencing on the Illumina platform. Library preparation and capture experiments were performed using the Agilent SureSelect Human All Exon V6 kit, strictly adhering to the reagents and consumables recommended in the instructions and following the latest optimized experimental procedures.

[0127] Basic experimental procedure: Genomic DNA is randomly fragmented into 180-280 bp fragments using a Covaris disruptor. After end repair and A-tailing, adapters are ligated to both ends of the fragments to prepare DNA libraries. The libraries with specific indexes are pooled and hybridized to biotin-labeled probes in liquid chromatography. Exons are then captured using streptomycin-containing magnetic beads, amplified by PCR, and subjected to library quality control. Once qualified, sequencing can proceed.

[0128] 3 warehouse inspection

[0129] After the library was constructed, it was first quantified using Qubit 2.0, and then the insert size of the library was detected using NGS3K / Caliper. After the insert size met the expectations, the effective concentration (3nM) of the library was accurately quantified using qPCR to ensure the quality of the library.

[0130] 4. Sequencing

[0131] Once the library passes inspection, sequencing is performed using the Illumina platform based on the effective concentration of the library and the data output requirements.

[0132] III. Bioinformatics Analysis Workflow

[0133] After obtaining the raw sequencing reads, a reference sequence or reference genome is available. GRCh37 In the case of / hg19), the information analysis process generally includes the following three parts:

[0134] 1) Sequencing data quality assessment: This mainly involves statistical analysis of sequencing error rate, data volume, and alignment rate to assess whether the library construction and sequencing have met the standards. If they meet the standards, further analysis can be performed; otherwise, the library needs to be reconstructed or additional sequencing needs to be performed.

[0135] 2) Variation detection: High-quality sequences are aligned to the human reference genome to detect variation information in the sample, and the detected variations are statistically analyzed and annotated.

[0136] 3) Variant screening and prediction of disease association: Based on the results of variant detection, harmful variant sites or genes associated with the disease are screened out through three analysis strategies: based on variant harmfulness, sample conditions, and based on gene function and phenotype.

[0137] IV. Data Quality Control

[0138] 1. Raw sequence data

[0139] The raw image data files obtained from high-throughput sequencing are converted into raw sequencing reads (Raw Data) through base calling analysis. The results are stored in FASTQ (fq) file format, which contains the sequence information of the sequencing reads and their corresponding sequencing quality information.

[0140] 2. Sequencing data quality assessment

[0141] 2.1 Sequencing Data Filtering

[0142] The raw sequencing results contain low-quality reads with adapters. To ensure the quality of information analysis, the raw reads need to be finely filtered to obtain clean reads, and subsequent analyses are based on these clean reads.

[0143] The data processing steps are as follows:

[0144] (1) Remove reads pairs with adapters;

[0145] (2) When the proportion of N (N means that the base information cannot be determined) in a single-end sequencing read is greater than 10%, this pair of reads needs to be removed;

[0146] (3) When the number of low-quality (less than 5) bases in a single-end sequencing read exceeds 50% of the length of the read, the read pair needs to be removed.

[0147] DNA-Seq adapter (Oligonucleotide sequences for TruSeq) TM Information on DNA Sample Prep Kits:

[0148] 5'Adapter:

[0149] 5'-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAGCGCTCTTCCGATCT-3'

[0150] 3'Adapter:

[0151] 5'-GATCGGAAGAGCACACGTCTGAACTCCAGTCAC (6th index)ATCTCGTATGCCGTCTTCTGCTTG-3'.

[0152] 2.2 Sequencing error rate distribution check

[0153] Phred score (Q) for each base sequenced phred The error rate is obtained by converting the sequencing error rate using Formula 1. The sequencing error rate is calculated during base calling using a model that determines the probability of errors occurring.

[0154] 2.3 Distribution of average quality values ​​of sequencing data

[0155] The quality of sequencing data is primarily above Q30 (≥80%) to ensure the smooth progress of subsequent analyses. Due to the characteristics of sequencing technology, the base quality at the ends of sequencing fragments is generally lower than that at the beginning.

[0156] 2.4 Summary of Sequencing Data Quality

[0157] Based on Illumina's sequencing characteristics, paired-end sequencing data are required to have an average Q20 percentage of over 90%, an average Q30 percentage of over 80%, and an average error rate of less than 0.1%.

[0158] 3. Sequencing depth and coverage statistics

[0159] Valid sequencing data through BWA (Li H et al.) Aligned with a reference genome ( GRCh37 / hg19), obtained BAM Format The initial alignment results. Then, using... SAMtools (Li H et al.) Compare and sort the results; then use... Sambamba Duplicate reads are marked. Finally, the alignment results after marking duplicate reads are used to perform statistical analysis on coverage, depth, etc. Typically, sequencing reads from human samples can achieve an alignment rate of over 95%; when the base coverage depth (read depth) of a site reaches 10X or more, the SNP detected at that site is relatively reliable.

[0160] Sequencing depth of some samples, such as Figure 1As shown, the left figure shows the base proportions at different sequencing depths. The horizontal axis represents the sequencing depth, and the vertical axis represents the proportion of bases with a sequencing depth of x in all bases. The image generally shows a Poisson distribution around the average depth. The right figure shows the cumulative base proportions at different depths. The horizontal axis represents the sequencing depth, and the vertical axis represents the proportion of bases with a sequencing depth greater than x in all bases. For example, a sequencing depth of 0 corresponds to a base proportion of 100%, meaning that 100% of the bases have a sequencing depth greater than 0.

[0161] The coverage depth (left coordinate) and coverage percentage (right coordinate) of each chromosome in a partial sample are shown below. Figure 2 As shown, the horizontal axis represents chromosome number, the left vertical axis represents average coverage depth, and the right vertical axis represents coverage rate. The coverage depth for each chromosome is calculated as: sequencing data volume of each chromosome / total length of exon regions on each chromosome. The coverage rate is calculated as: total length of covered chromosomes / total length of exon regions on each chromosome.

[0162] The inventors further analyzed the comparison rate and coverage.

[0163] 4-Gene-Disease Phenotype Association Analysis

[0164] 4.1 DisGeNet Database Annotation Results

[0165] The DisGeNet database is a database focused on gene-disease associations and mutation site-disease associations. The current version is V5.0, containing 561,119 gene-disease association records (GDAs) and 135,588 mutation-disease association records (VDAs). Using the association data in this database, screening for common mutated genes among samples identified 20 genes associated with acute exacerbations of COPD. These 20 genes are: ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB, and MRC2.

[0166] No corresponding information was detected for these 20 genes in DisGetNet.

[0167] 4.2 Phenolyzer Analysis Results

[0168] In disease research, determining the association between candidate genes and diseases is crucial. Based on the disease / phenotype names provided by the user, a precise algorithm, combined with sequencing results and multiple databases, is used to screen and rank genes, constructing a gene-disease phenotype association graph. The strength of the association between genes and acute exacerbations of COPD is ranked as follows: Figure 3-4 As shown in Table 3-4, the correlation score is 1 as the highest.

[0169] Specifically, the mutation details of each gene are as follows:

[0170] ITK gene: Mutations 1-3.

[0171] Mutation 1: Priority annotation H, mutation at 156608135 on chromosome 5, REF / ALT: G / T; ITK (T-cell-specific tyrosine kinase; homolog of mouse T-cell itk / tsk tyrosine kinase), NM_005546: exon1: c.138+9G>T, 5q33.3; P / N: 0 / 1.

[0172] Mutation 2: Priority annotation H, mutation at 156635995 on chromosome 5, REF / ALT: C / G; ITK (T-cell-specific tyrosine kinase; homolog of mouse T-cell itk / tsk tyrosine kinase), 5q33.3; P / N: 1 / 0.

[0173] Mutation 3: Priority annotation H, mutation at 156675967 on chromosome 5, rs34482255, REF / ALT: C / T; ITK (T-cell-specific tyrosine kinase; homolog of mouse T-cell itk / tsk tyrosine kinase), 5q33.3; P / N: 0 / 1.

[0174] ROCK1 gene: mutation 4-5.

[0175] Mutation 4: Priority annotation H+, mutation at 18562720 on chromosome 18, REF / ALT: T / C; ROCK1 (RHO-associated coiled-coil-containing protein kinase 1), NM_005406:exon21:c.2559+4A>G, 18q11.1; P / N: 1 / 0.

[0176] Mutation 5: Priority annotation H+, mutation at 18619507 on chromosome 18, rs370467228, REF / ALT: C / T; ROCK1 (RHO-associated coiled-coil-containing protein kinase 1), 18q11.1; P / N: 1 / 0.

[0177] ADCY9 gene: Mutation 6.

[0178] Mutation 6: Priority annotation H+, mutation at position 4165128 on chromosome 16, REF / ALT: C / A; ADCY9 (Adenylate cyclase-9), 16p13.3; P / N: 1 / 0.

[0179] ITGA2B gene: mutation 7-10.

[0180] Mutation 7: Priority annotation H, mutation at 42449770 on chromosome 17, rs761164933, REF / ALT: G / A; ITGA2B (Integrin, alpha-2b (platelet glycoprotein IIb of IIb / IIIa complex, antigen CD41B)), 17q21.31; P / N: 1 / 0.

[0181] Mutation 8: Priority annotation H, mutation at 42457115 on chromosome 17, rs539187844, REF / ALT: G / A; ITGA2B (Integrin, alpha-2b (platelet glycoprotein IIb of IIb / IIIa complex, antigen CD41B)), 17q21.31; P / N: 0 / 1.

[0182] Mutation 9: Priority annotation H, mutation at 42460918 on chromosome 17, REF / ALT: C / T; ITGA2B (Integrin, alpha-2b (platelet glycoprotein IIb of IIb / IIIa complex, antigenCD41B)), 17q21.31; P / N: 1 / 0.

[0183] Mutation 10: Priority annotation H, mutation at 42462982 on chromosome 17, rs749432805, REF / ALT: G / C; ITGA2B (Integrin, alpha-2b (platelet glycoprotein IIb of IIb / IIIa complex, antigen CD41B)), 17q21.31; P / N: 1 / 0.

[0184] PDGFRB gene: mutations 11-13.

[0185] Mutation 11: Priority annotation H, mutation at 149497184 on chromosome 5, rs754945283, REF / ALT: G / A; PDGFRB (Platelet-derived growth factor receptor, beta polypeptide), 5q32; P / N: 1 / 0.

[0186] Mutation 12: Priority annotation H, mutation at 149503834 on chromosome 5, rs768318526, REF / ALT: A / T; PDGFRB (Platelet-derived growth factor receptor, beta polypeptide), 5q32; P / N: 1 / 0.

[0187] Mutation 13: Priority annotation H, mutation at 149512332 on chromosome 5, rs200684708, REF / ALT: G / A; PDGFRB (Platelet-derived growth factor receptor, beta polypeptide), 5q32; P / N: 2 / 0.

[0188] FGFR3 gene: mutation 14-19.

[0189] Mutation 14: Priority annotation H, mutation at 1795748 on chromosome 4, rs553265665, REF / ALT: G / C; FGFR3 (Fibroblast growth factor receptor-3), 4p16.3; P / N: 1 / 0.

[0190] Mutation 15: Priority annotation H, mutation at 1803138 on chromosome 4, rs577990843, REF / ALT: C / G; FGFR3 (Fibroblast growth factor receptor-3), 4p16.3; P / N: 0 / 1.

[0191] Mutation 16: Priority annotation H, mutation at 1806569 on chromosome 4, rs182935140, REF / ALT: G / A; FGFR3 (Fibroblast growth factor receptor-3), 4p16.3; P / N: 1 / 0.

[0192] Mutation 17: Priority annotation H, mutation at 1807899 on chromosome 4, REF / ALT: A / C; FGFR3 (Fibroblast growth factor receptor-3), 4p16.3; P / N: 0 / 1.

[0193] Mutation 18: Priority annotation H, mutation at 1808659 on chromosome 4, rs56266857, REF / ALT: G / A; FGFR3 (Fibroblast growth factor receptor-3), 4p16.3; P / N: 1 / 0.

[0194] Mutation 19: Priority annotation H, mutation at 1808952 on chromosome 4, REF / ALT: C / T; FGFR3 (Fibroblast growth factor receptor-3), 4p16.3; P / N: 1 / 0.

[0195] SERPINA3 gene: mutation 20-23.

[0196] Mutation 20: Priority annotation H, mutation at 95081148 on chromosome 14, rs116880457, REF / ALT: C / T; SERPINA3 (Alpha-1-antichymotrypsin), 14q32.13; P / N: 0 / 1.

[0197] Mutation 21: Priority annotation H, mutation at position 95085620 on chromosome 14, REF / ALT: G / A; SERPINA3 (Alpha-1-antichymotrypsin), 14q32.13; P / N: 1 / 0.

[0198] Mutation 22: Priority annotation H, mutation at 95085652 on chromosome 14, rs536399107, REF / ALT: G / A; SERPINA3 (Alpha-1-antichymotrypsin), 14q32.13; P / N: 1 / 0.

[0199] Mutation 23: Priority annotation H, mutation at 95088683 on chromosome 14, rs142398813, REF / ALT: T / C; SERPINA3 (Alpha-1-antichymotrypsin), 14q32.13; P / N: 1 / 0.

[0200] ITPR1 gene: Mutation 24-26.

[0201] Mutation 24: Priority annotation H, mutation at 4715070 on chromosome 3, rs200199463, REF / ALT: G / A; ITPR1 (Inositol 1,4,5-triphosphate receptor, type 1), 3p26.1; P / N: 1 / 0.

[0202] Mutation 25: Priority annotation H, mutation at 4808292 on chromosome 3, REF / ALT: G / A; ITPR1 (Inositol 1,4,5-triphosphate receptor, type 1), 3p26.1; P / N: 1 / 0.

[0203] Mutation 26: Priority annotation H, mutation at 4856139 on chromosome 3, rs367632214, REF / ALT: A / G; ITPR1 (Inositol 1,4,5-triphosphate receptor, type 1), 3p26.1; P / N: 1 / 0.

[0204] CFTR gene: Mutation 27-33.

[0205] Mutation 27: Priority annotation H, mutation at 117171053 on chromosome 7, rs141723617, REF / ALT: T / C; CFTR (Cystic fibrosis transmembrane conductance regulator (ATP-bindingcassette, subfamily C, member 7)), 7q31.2; P / N: 2 / 0.

[0206] Mutation 28: Priority annotation H, mutation at 117171122 on chromosome 7, rs35516286, REF / ALT: T / C; CFTR (Cystic fibrosis transmembrane conductance regulator (ATP-bindingcassette, subfamily C, member 7)), 7q31.2; P / N: 1 / 0.

[0207] Mutation 29: Priority annotation H, mutation at 117175372 on chromosome 7, rs121909046, REF / ALT: A / G; CFTR (Cystic fibrosis transmembrane conductance regulator (ATP-bindingcassette, subfamily C, member 7)), 7q31.2; P / N: 2 / 0.

[0208] Mutation 30: Priority annotation H, mutation at 117176719 on chromosome 7, rs112162204, REF / ALT: C / G; CFTR (Cystic fibrosis transmembrane conductance regulator (ATP-bindingcassette, subfamily C, member 7)), 7q31.2; P / N: 0 / 1.

[0209] Mutation 31: Priority annotation H, mutation at 117267592 on chromosome 7, rs1800120, REF / ALT: G / A; CFTR (Cystic fibrosis transmembrane conductance regulator (ATP-bindingcassette, subfamily C, member 7)), 7q31.2; P / N: 1 / 0.

[0210] Mutation 32: Priority annotation H, mutation at 117267766 on chromosome 7, rs1800123, REF / ALT: C / T; CFTR (Cystic fibrosis transmembrane conductance regulator (ATP-bindingcassette, subfamily C, member 7)), 7q31.2; P / N: 1 / 0.

[0211] Mutation 33: Priority annotation H, mutation at 117304869 on chromosome 7, rs397508670, REF / ALT: C / T; CFTR (Cystic fibrosis transmembrane conductance regulator (ATP-bindingcassette, subfamily C, member 7)), 7q31.2; P / N: 1 / 0.

[0212] USP24 gene: mutation 34-40.

[0213] Mutation 34: Priority annotation H, mutation at position 55559639 on chromosome 1, REF / ALT: C / A; USP24 (Ubiquitin-specific protease 24), 1p32.3; P / N: 1 / 0.

[0214] Mutation 35: Priority annotation H, mutation at position 55569610 on chromosome 1, REF / ALT: A / G; USP24 (Ubiquitin-specific protease 24), 1p32.3; P / N: 1 / 0.

[0215] Mutation 36: Priority annotation H, mutation at 55603184 on chromosome 1, rs185201791, REF / ALT: G / A; USP24 (Ubiquitin-specific protease 24), NM_015306: exon28: c.3201+4C>T, 1p32.3; P / N: 1 / 0.

[0216] Mutation 37: Priority annotation H, mutation at 55604394 on chromosome 1, REF / ALT: T / C; USP24 (Ubiquitin-specific protease 24), NM_015306: exon26: c.2818-3A>G, 1p32.3; P / N: 1 / 0.

[0217] Mutation 38: Priority annotation H, mutation at 55613326 on chromosome 1, rs190706465, REF / ALT: C / T; USP24 (Ubiquitin-specific protease 24), 1p32.3; P / N: 1 / 0.

[0218] Mutation 39: Priority annotation H, mutation at 55631552 on chromosome 1, rs142154143, REF / ALT: A / T; USP24 (Ubiquitin-specific protease 24), NM_015306:exon7:c.927+6T>A, 1p32.3; P / N: 1 / 0.

[0219] Mutation 40: Priority annotation H, mutation at 55631613 on chromosome 1, REF / ALT: A / T; USP24 (Ubiquitin-specific protease 24), 1p32.3; P / N: 1 / 0.

[0220] SAA1 gene: mutation 41.

[0221] Mutation 41: Priority annotation L, mutation at 18291340 on chromosome 11, rs776323374, REF / ALT: T / C; SAA1 (Serum amyloid A1), 11p15.1; P / N: 0 / 1.

[0222] TEK gene: mutation 42-44.

[0223] Mutation 42: Priority annotation H, mutation at 27204927 on chromosome 9, rs202131936, REF / ALT: G / C; TEK (TEK tyrosine kinase, endothelial), 9p21.2; P / N: 1 / 1.

[0224] Mutation 43: Priority annotation H, mutation at 27220040 on chromosome 9, rs201242194, REF / ALT: C / G; TEK (TEK tyrosine kinase, endothelial), NM_000459:exon21:c.3104-7C>G; NM_001290077:exon20:c.2975-7C>G; NM_001290078:exon19:c.2660-7C>G, 9p21.2; P / N: 1 / 0.

[0225] Mutation 44: Priority annotation H, mutation at 27228307 on chromosome 9, REF / ALT: A / C; TEK (TEKtyrosine kinase, endothelial), NM_000459: exon22: c.3300+4A>C; NM_001290077: exon21: c.3171+4A>C; NM_001290078: exon20: c.2856+4A>C, 9p21.2; P / N: 1 / 0.

[0226] SPTBN2 gene: mutation 45-50.

[0227] Mutation 45: Priority annotation H-, mutation at 66455721 on chromosome 11, rs571837788, REF / ALT: G / A; SPTBN2(Spectrin,beta,nonerythrocytic,2), 11q13.2; P / N: 1 / 0.

[0228] Mutation 46: Priority annotation H-, mutation at 66457417 on chromosome 11, rs750335105, REF / ALT: G / T; SPTBN2(Spectrin, beta, nonerythrocytic, 2), NM_006946: exon28: c.5811-3C>A, 11q13.2; P / N: 1 / 0.

[0229] Mutation 47: Priority annotation H-, mutation at 66460505 on chromosome 11, rs143640999, REF / ALT: C / T; SPTBN2(Spectrin,beta,nonerythrocytic,2), 11q13.2; P / N: 1 / 0.

[0230] Mutation 48: Priority annotation H-, mutation at 66461669 on chromosome 11, rs373270554, REF / ALT: G / A; SPTBN2(Spectrin,beta,nonerythrocytic,2), 11q13.2; P / N: 0 / 1.

[0231] Mutation 49: Priority annotation H-, mutation at 66472288 on chromosome 11, rs548188891, REF / ALT: G / A; SPTBN2(Spectrin,beta,nonerythrocytic,2), 11q13.2; P / N: 0 / 1.

[0232] Mutation 50: Priority annotation H-, mutation at position 66472461 on chromosome 11, REF / ALT: C / A; SPTBN2(Spectrin,beta,nonerythrocytic,2), 11q13.2; P / N: 1 / 0.

[0233] PLXNA4 gene: mutation 51-56.

[0234] Mutation 51: Priority annotation H, mutation at 131817833 on chromosome 7, rs200763664, REF / ALT: G / A; PLXNA4 (Plexin A4), 7q32.3; P / N: 2 / 0.

[0235] Mutation 52: Priority annotation H, mutation at 131870101 on chromosome 7, REF / ALT: C / T; PLXNA4 (Plexin A4), 7q32.3; P / N: 0 / 1.

[0236] Mutation 53: Priority annotation H, mutation at 131908288 on chromosome 7, rs138963899, REF / ALT: C / T; PLXNA4 (Plexin A4), 7q32.3; P / N: 1 / 0.

[0237] Mutation 54: Priority annotation H, mutation at 131908302 on chromosome 7, rs200493064, REF / ALT: C / T; PLXNA4 (Plexin A4), 7q32.3; P / N: 1 / 0.

[0238] Mutation 55: Priority annotation H, mutation at 132174160 on chromosome 7, rs754782288, REF / ALT: C / T; PLXNA4 (Plexin A4), 7q32.3; P / N: 1 / 0.

[0239] Mutation 56: Priority annotation H, mutation at 132192417 on chromosome 7, rs779570289, REF / ALT: T / G; PLXNA4 (Plexin A4), 7q32.3; P / N: 1 / 0.

[0240] SPTA1 gene: mutation 57-65.

[0241] Mutation 57: Priority annotation H, mutation at 158582725 on chromosome 1, REF / ALT: T / G; SPTA1(Spectrin,alpha,erythrocytic-1), 1q23.1; P / N: 1 / 0.

[0242] Mutation 58: Priority annotation H, mutation at 158590207 on chromosome 1, rs761106571, REF / ALT: T / C; SPTA1(Spectrin,alpha,erythrocytic-1), 1q23.1; P / N: 0 / 1.

[0243] Mutation 59: Priority annotation H, mutation at 158592822 on chromosome 1, rs768854133, REF / ALT: G / A; SPTA1(Spectrin,alpha,erythrocytic-1), 1q23.1; P / N: 1 / 0.

[0244] Mutation 60: Priority annotation H, mutation at 158597458 on chromosome 1, rs201233455, REF / ALT: C / T; SPTA1(Spectrin,alpha,erythrocytic-1), 1q23.1; P / N: 0 / 1.

[0245] Mutation 61: Priority annotation H, mutation at 158606509 on chromosome 1, rs749176177, REF / ALT: A / T; SPTA1(Spectrin,alpha,erythrocytic-1), 1q23.1; P / N: 0 / 1.

[0246] Mutation 62: Priority annotation H, mutation at 158613136 on chromosome 1, rs187916559, REF / ALT: G / A; SPTA1(Spectrin,alpha,erythrocytic-1), 1q23.1; P / N: 0 / 1.

[0247] Mutation 63: Priority annotation H, mutation at 158613172 on chromosome 1, REF / ALT: A / G; SPTA1(Spectrin,alpha,erythrocytic-1), 1q23.1; P / N: 1 / 0.

[0248] Mutation 64: Priority annotation H, mutation at 158637705 on chromosome 1, rs747716571, REF / ALT: G / A; SPTA1(Spectrin,alpha,erythrocytic-1), 1q23.1; P / N: 1 / 0.

[0249] Mutation 65: Priority annotation H, mutation at 158653225 on chromosome 1, rs3737521, REF / ALT: G / A; SPTA1(Spectrin,alpha,erythrocytic-1), 1q23.1; P / N: 2 / 0.

[0250] PLG gene: Mutation 66.

[0251] Mutation 66: Priority annotation H, mutation at 161152897 on chromosome 6, rs747448179, REF / ALT: C / G; PLG (Plasminogen), 6q26; P / N: 1 / 0.

[0252] MAPKAPK2 gene: mutation 67-68.

[0253] Mutation 67: Priority annotation H-, mutation at 206903451 on chromosome 1, REF / ALT: C / T; MAPKAPK2 (Mitogen-activated protein kinase-activated protein kinase 2), NM_004759:exon5:c.691+8C>T; NM_032960:exon5:c.691+8C>T, 1q32.1; P / N: 1 / 0.

[0254] Mutation 68: Priority annotation L-, mutation at 206904606 on chromosome 1, REF / ALT: A / G; MAPKAPK2 (Mitogen-activated protein kinase-activated protein kinase 2), 1q32.1; P / N: 1 / 0.

[0255] LAMA3 gene: mutation 69-76.

[0256] Mutation 69: Priority annotation H, mutation at 21422714 on chromosome 18, REF / ALT: G / T; LAMA3(Laminin,alpha-3(nicein,150kD;kalinin,165kD;BM600,150kD;epiligrin)), 18q11.2; P / N: 0 / 1.

[0257] Mutation 70: Priority annotation H, mutation at 21447864 on chromosome 18, rs552326056, REF / ALT: C / T; LAMA3(Laminin,alpha-3(nicein,150kD;kalinin,165kD;BM600,150kD;epiligrin)), 18q11.2; P / N: 1 / 1.

[0258] Mutation 71: Priority annotation H, mutation at 21474864 on chromosome 18, rs766873824, REF / ALT: C / T; LAMA3(Laminin,alpha-3(nicein,150kD;kalinin,165kD;BM600,150kD;epiligrin)), NM_000227:exon7:c.635-7C>T; NM_001127717:exon44:c.5462-7C>T; NM_001127718:exon7:c.635-7C>T; NM_198129:exon44:c.5462-7C>T, 18q11.2; P / N: 0 / 1.

[0259] Mutation 72: Priority annotation H, mutation at 21494393 on chromosome 18, rs184581808, REF / ALT: G / T; LAMA3(Laminin,alpha-3(nicein,150kD;kalinin,165kD;BM600,150kD;epiligrin)), 18q11.2; P / N: 0 / 1.

[0260] Mutation 73: Priority annotation H, mutation at 21495335 on chromosome 18, rs781529313, REF / ALT: A / G; LAMA3(Laminin,alpha-3(nicein,150kD;kalinin,165kD;BM600,150kD;epiligrin)), 18q11.2; P / N: 1 / 0.

[0261] Mutation 74: Priority annotation H, mutation at 21508101 on chromosome 18, rs776754771, REF / ALT: C / T; LAMA3(Laminin,alpha-3(nicein,150kD;kalinin,165kD;BM600,150kD;epiligrin)), 18q11.2; P / N: 0 / 1.

[0262] Mutation 75: Priority annotation H, mutation at 21523934 on chromosome 18, rs117056996, REF / ALT: C / T; LAMA3(Laminin,alpha-3(nicein,150kD;kalinin,165kD;BM600,150kD;epiligrin)), 18q11.2; P / N: 0 / 1.

[0263] Mutation 76: Priority annotation H, mutation at 21530049 on chromosome 18, REF / ALT: A / C; LAMA3(Laminin,alpha-3(nicein,150kD;kalinin,165kD;BM600,150kD;epiligrin)), 18q11.2; P / N: 1 / 0.

[0264] P4HB gene: mutation 77-78.

[0265] Mutation 77: Priority annotation H+, mutation at 79804369 on chromosome 17, rs200205336, REF / ALT: G / A; P4HB (Procollagen-proline, 2-oxoglutarate-4-dioxygenase, beta polypeptide), 17q25.3; P / N: 1 / 0.

[0266] Mutation 78: Priority annotation H+, mutation at 79804909 on chromosome 17, rs756125688, REF / ALT: T / C; P4HB (Procollagen-proline, 2-oxoglutarate-4-dioxygenase, beta polypeptide), 17q25.3; P / N: 0 / 1.

[0267] MRC2 gene: mutation 79-80.

[0268] Mutation 79: Priority annotation L, mutation at 60751531 on chromosome 17, rs575846013, REF / ALT: G / A; MRC2 (Mannose receptor, C-type, 2), 17q23.2; P / N: 0 / 1.

[0269] Mutation 80: Priority annotation H, mutation at 60768366 on chromosome 17, REF / ALT: C / T; MRC2 (Mannose receptor, C-type, 2), 17q23.2; P / N: 1 / 0.

[0270] Where REF / ALT represents the reference genome base type / sample genome base type; P / N represents the number of COPD patients with acute exacerbations / number of COPD patients with stable conditions who had mutations at this site in the initial cohort and validation cohort.

[0271] Table 3. Ranking information of candidate genes in the initial cohort

[0272]

[0273]

[0274] Table 4. Ranking information of candidate genes in the validation cohort

[0275] Gene ranking Gene name Gene ID in NCBI Gene score 1 ITK 3702 0.1675 2 PLCG2 5336 0.1577 3 ROCK1 6093 0.1534 4 ADCY9 115 0.1529 5 ITGA2B 3674 0.1517 6 PDGFRB 5159 0.145 7 CAMK2G 818 0.1405 8 MTOR 2475 0.1383 9 FN1 2335 0.1379 10 FGFR3 2261 0.1371 11 SERPINA3 12 0.1367 12 ITPR1 3708 0.1365 13 CFTR 1080 0.1241 14 USP24 23358 0.1237 15 SAA1 6288 0.1229 16 TEK 7010 0.1208 17 SOS2 6655 0.1198 18 SPTBN2 6712 0.1198 19 ARHGEF7 8874 0.1184 20 ALDOA 226 0.1119

[0276] Note: Bold text indicates genes that are identical to those in the validation queue and the initial queue.

[0277] Subsequent validation cohort analysis revealed 13 overlapping genes among the top 20 associated genes. The ITK gene (IL2-inducible T-cell kinase) had the highest gene score and was considered the most likely AECOPD susceptibility gene. The remaining genes were ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, and SPTBN2. GO enrichment analysis of gene function at these sites further revealed pathway abnormalities involved in these AECOPD susceptibility genes.

[0278] GO enrichment analysis of SNP sites

[0279] Functional Classification path Gene p-value MF ion binding GO:0043167 <![CDATA[5.6×10 -18 ]]> MF molecular_function GO:0003674 <![CDATA[5.6×10 -16 ]]> MF catalytic activity GO:0003824 <![CDATA[9.3×10 -14 ]]> BP single-organism process GO:0044699 <![CDATA[1.7×10 -21 ]]> BP single-organism cellular process GO:0044763 <![CDATA[9.5×10 -18 ]]> BP xenobiotic glucuronidation GO:0052697 <![CDATA[6.5×10 -17 ]]> CC membrane-bound vesicle GO:0031988 <![CDATA[1.9×10 -13 ]]> CC vesicle GO:0031982 <![CDATA[3.1×10 -13 ]]> CC cytoplasmic part GO:0044444 <![CDATA[6.5×10 -13 ]]>

[0280] Note: MF represents molecular function, BP represents biological pathway, CC represents cellular component, and P < 0.05 indicates that the pathway is statistically significant.

[0281] Subsequent validation cohort analysis revealed 13 overlapping genes among the top 20 associated genes. The ITK gene (IL2-inducible T-cell kinase) consistently had the highest gene scores, followed by ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, and SPTBN2. Area under the curve (AUC) analysis was performed on these 13 genes in patients with stable COPD and those experiencing acute exacerbations. The mutation sites involved in each gene were those listed above. The AUC was 0.634, p = 0.042, with a specificity of 68.7% and a sensitivity of 58%. The area under the curve (AUC) of the first 20 genes (ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB, and MRC2) was analyzed in patients with stable COPD and patients with acute exacerbations of COPD. The mutation sites involved in each gene were the mutation sites listed above. The AUC was 0.569, p = 0.296, the specificity was 43.7%, and the sensitivity was 70%.

[0282] The area under the curve (AUC) of the genes ROCK1, ITGA2B, PDGFRB, FGFR3, ITPR1, USP24, TEK, and SPTBN2 in combination was analyzed in patients with stable COPD and patients with acute exacerbations of COPD. The mutation sites involved in each gene were the mutation sites listed above. The AUC was 0.616, p = 0.077, the specificity was 81.2%, and the sensitivity was 42.0%.

[0283] Among them, the analysis of each gene ( Figure 5 )as follows:

[0284] Whole exome analysis of peripheral blood from patients with acute exacerbations of COPD revealed that the area under the curve (AUC) for three ITK gene mutations in patients with stable COPD and patients with acute exacerbations of COPD was 0.479, p = 0.747, with a specificity of 93.7% and a sensitivity of 2%.

[0285] Area under the curve analysis of two mutations in the ROCK1 gene in patients with stable COPD and patients with acute exacerbations of COPD showed an area under the curve of 0.520, p = 0.761, with a specificity of 100% and a sensitivity of 4%.

[0286] The area under the curve (AUC) analysis of one mutation in the ADCY9 gene in patients with stable COPD and patients with acute exacerbations of COPD showed an AUC of 0.510, p = 0.879, with a specificity of 100% and a sensitivity of 2%.

[0287] Area under the curve analysis of four mutations in the ITGA2B gene in patients with stable COPD and patients with acute exacerbations of COPD showed an area under the curve of 0.514, p = 0.827, with a specificity of 96.9% and a sensitivity of 6%.

[0288] The area under the curve (AUC) analysis of three mutations in the PDGFRB gene in patients with stable COPD and patients with acute exacerbations of COPD showed an AUC of 0.540, p = 0.543, with a specificity of 100% and a sensitivity of 8%.

[0289] The area under the curve (AUC) analysis of six mutations in the FGFR3 gene in patients with stable COPD and patients with acute exacerbations of COPD showed an AUC of 0.509, p = 0.066, with a specificity of 93.7% and a sensitivity of 8%.

[0290] Area under the curve analysis of four mutations in the SERPINA3 gene in patients with stable COPD and patients with acute exacerbations of COPD showed an area under the curve of 0.514, p = 0.827, with a specificity of 96.9% and a sensitivity of 6%.

[0291] The area under the curve (AUC) analysis of three ITPR1 gene mutations in patients with stable COPD and patients with acute exacerbations of COPD showed an AUC of 0.530, p = 0.648, with a specificity of 100% and a sensitivity of 6%.

[0292] The area under the curve (AUC) analysis of seven mutations in the CFTR gene in patients with stable COPD and patients with acute exacerbations of COPD showed an AUC of 0.559, p = 0.372, with a specificity of 93.7% and a sensitivity of 18%.

[0293] The area under the curve (AUC) analysis of seven mutations in the USP24 gene in patients with stable COPD and patients with acute exacerbations of COPD showed an AUC of 0.570, p = 0.287, with a specificity of 100% and a sensitivity of 14%.

[0294] Area under the curve analysis of one mutation in the SAA1 gene in patients with stable COPD and patients with acute exacerbations of COPD showed an area under the curve of 0.510, p = 0.879, with a specificity of 100% and a sensitivity of 2%.

[0295] Area under the curve analysis of three TEK gene mutations in patients with stable COPD and patients with acute exacerbations of COPD showed an area under the curve of 0.514, p = 0.827, with a specificity of 96.9% and a sensitivity of 6%.

[0296] The area under the curve (AUC) analysis of six mutations in the SPTBN2 gene in patients with stable COPD and patients with acute exacerbations of COPD showed an AUC of 0.509, p = 0.894, with a specificity of 93.7% and a sensitivity of 8%.

[0297] The area under the curve (AUC) analysis of six mutations in the PLXNA4 gene in patients with stable COPD and patients with acute exacerbations of COPD showed an AUC of 0.544, p = 0.500, with a specificity of 96.9% and a sensitivity of 12%.

[0298] The area under the curve (AUC) analysis of nine mutations in the SPTA1 gene in patients with stable COPD and patients with acute exacerbations of COPD showed an AUC of 0.498, p = 0.970, with a specificity of 87.5% and a sensitivity of 12%.

[0299] Area under the curve analysis of one mutation in the PLG gene in patients with stable COPD and patients with acute exacerbations of COPD showed an area under the curve of 0.510, p = 0.879, with a specificity of 100% and a sensitivity of 2%.

[0300] Area under the curve analysis of two mutations in the MAPKAPK2 gene in patients with stable COPD and patients with acute exacerbations of COPD showed an area under the curve of 0.520, p = 0.761, with a specificity of 100% and a sensitivity of 4%.

[0301] The area under the curve (AUC) analysis of eight mutations in the LAMA3 gene in patients with stable COPD and patients with acute exacerbations of COPD showed an AUC of 0.452, p = 0.464, with a specificity of 84.4% and a sensitivity of 6%.

[0302] Area under the curve analysis of two mutations in the P4HB gene in patients with stable COPD and patients with acute exacerbations of COPD showed an area under the curve of 0.494, p = 0.932, with a specificity of 96.9% and a sensitivity of 2%.

[0303] Area under the curve analysis of two mutations in the MRC2 gene in patients with stable COPD and patients with acute exacerbations of COPD showed an area under the curve of 0.494, p = 0.932, with a specificity of 96.9% and a sensitivity of 2%.

[0304] The sites involved in each gene are the mutation sites given above.

[0305] The present invention has been described in detail above. For those skilled in the art, the invention can be practiced in a wide range of ways with equivalent parameters, concentrations, and conditions without departing from its spirit and scope, and without requiring unnecessary experiments. Although specific embodiments have been given, it should be understood that further modifications can be made to the invention. In summary, according to the principles of the invention, this application is intended to include any changes, uses, or improvements to the invention, including changes made using conventional techniques known in the art that depart from the scope disclosed herein. Some of the essential features can be applied within the scope of the following appended claims.

Claims

1. Use of a reagent for detecting whether a susceptible gene of a test subject has mutated in the preparation of a product for assisting in predicting whether the test subject is susceptible to acute exacerbation of COPD; the susceptible genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK and SPTBN2 genes; or ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and MRC2 genes; Or it may be ROCK1, ITGA2B, PDGFRB, FGFR3, ITPR1, USP24, TEK and SPTBN2 genes.

2. Use of a reagent for detecting whether a test subject contains a susceptible gene in the preparation of a product for assisting in predicting whether the test subject is susceptible to acute exacerbation of COPD; the susceptible genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK and SPTBN2 genes; or ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and MRC2 genes; Or it may be ROCK1, ITGA2B, PDGFRB, FGFR3, ITPR1, USP24, TEK and SPTBN2 genes.

3. Use of a reagent for detecting the expression of susceptible genes of a test subject in the preparation of a product for assisting in predicting whether the test subject is susceptible to acute exacerbation of COPD; the susceptible genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK and SPTBN2 genes; or ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and MRC2 genes; Or it may be ROCK1, ITGA2B, PDGFRB, FGFR3, ITPR1, USP24, TEK and SPTBN2 genes.

4. Use of a reagent for detecting whether a susceptible gene of a test object has mutated in the preparation of a product for assisting in screening patients susceptible to acute exacerbation of COPD; the susceptible genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK and SPTBN2 genes; or ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and MRC2 genes; Or it may be ROCK1, ITGA2B, PDGFRB, FGFR3, ITPR1, USP24, TEK and SPTBN2 genes.

5. Use of a reagent for detecting whether a test object contains a susceptible gene in the preparation of a product for assisting in screening patients susceptible to acute exacerbation of COPD; the susceptible genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK and SPTBN2 genes; or ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and MRC2 genes; Or it may be ROCK1, ITGA2B, PDGFRB, FGFR3, ITPR1, USP24, TEK and SPTBN2 genes.

6. Use of a reagent for detecting the expression of susceptible genes of a test object in the preparation of a product for assisting in screening patients susceptible to acute exacerbation of COPD; the susceptible genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK and SPTBN2 genes; or ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and MRC2 genes; Or it may be ROCK1, ITGA2B, PDGFRB, FGFR3, ITPR1, USP24, TEK and SPTBN2 genes.

7. Use of a reagent for detecting whether a susceptible gene of a test object has mutated in the preparation of a product for assisting in the diagnosis of acute exacerbation of chronic obstructive pulmonary disease; the susceptible genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK and SPTBN2 genes; or ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and MRC2 genes; Or it may be ROCK1, ITGA2B, PDGFRB, FGFR3, ITPR1, USP24, TEK and SPTBN2 genes.

8. Use of a reagent for detecting whether a test object contains a susceptible gene in the preparation of a product for auxiliary diagnosis of acute exacerbation of chronic obstructive pulmonary disease; the susceptible genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK and SPTBN2 genes; or ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and MRC2 genes; Or it may be ROCK1, ITGA2B, PDGFRB, FGFR3, ITPR1, USP24, TEK and SPTBN2 genes.

9. Use of a reagent for detecting the expression of susceptible genes of a test object in the preparation of a product for assisting the diagnosis of acute exacerbation of chronic obstructive pulmonary disease; the susceptible genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK and SPTBN2 genes; or ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and MRC2 genes; Or it may be ROCK1, ITGA2B, PDGFRB, FGFR3, ITPR1, USP24, TEK and SPTBN2 genes.

10. Reagents for detecting whether the susceptible gene of the subject to be tested has mutated; or, a reagent for detecting whether the subject to be tested contains a susceptible gene; Or, a reagent for detecting the expression level of a susceptible gene of a subject to be tested; The susceptibility genes are ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK and SPTBN2 genes; or ITK, ROCK1, ADCY9, ITGA2B, PDGFRB, FGFR3, SERPINA3, ITPR1, CFTR, USP24, SAA1, TEK, SPTBN2, PLXNA4, SPTA1, PLG, MAPKAPK2, LAMA3, P4HB and MRC2 genes; Or it may be ROCK1, ITGA2B, PDGFRB, FGFR3, ITPR1, USP24, TEK and SPTBN2 genes.

Citation Information

Patent Citations

  • Improved horseshoe

    US15306A